Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DatChem has developed a patented magnetic resonance-based diagnostic platform capable of recording the chemical state of human tissue in vivo using clinical MRI scanners. The technology enables early identification of disease risk or presence where no other diagnostic/prognostic options exist, such as pre-malignant breast cancer risk ("DatChem-Breast") and ADHD diagnosis/therapy monitoring ("DatChem-Neuro"). The company is pre-revenue, has raised A$1.1m from founders/investors/pro-bono clinicians, holds a portfolio of 6 patents and 12 PCT applications, and anticipates commercial launch post-FDA clearance in the US/EU/Australia
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DatChem.